Reverse Transcriptase Inhibitors
1 drugsAbout Reverse Transcriptase
Reverse transcriptase is an enzyme essential for retrovirus replication, catalyzing DNA synthesis from an RNA template. It plays a crucial role in the life cycle of viruses like HIV, making it a key target for antiviral therapies.
Inhibiting reverse transcriptase can effectively disrupt viral replication and slow disease progression. Currently, there is no genetic evidence directly linking reverse transcriptase to specific human diseases.
GENVOYA is the only FDA-approved drug targeting reverse transcriptase, developed by Gilead Sciences. It is a small molecule approved in 2015 for a single indication within the 'Other' therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Drug Interactions with only 1 trials.
Top Reverse Transcriptase Drugs
Gilead Sciences is the only company with an approved drug targeting reverse transcriptase.
The market is highly concentrated, indicating potential entry barriers or a lack of competitive innovation.
Reverse Transcriptase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Reverse Transcriptase, using small molecule modality.
Explore alternative modalities like antibodies or gene therapies to differentiate from existing treatments.
Reverse Transcriptase Clinical Trials 61 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 34 | 30 | 3 | 1 | 91% |
| Phase 2 | 5 | 2 | 1 | 2 | 67% |
| Phase 3 | 6 | 5 | 1 | 0 | 83% |
| Phase 4 | 16 | 9 | 3 | 4 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Reverse Transcriptase Drug Approval Timeline (2015 - 2015)
The first and only drug, GENVOYA, was approved in 2015.
The approval timeline suggests a potentially saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 64 clinical trials targeting Reverse Transcriptase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities